Research programme: diabetes therapy - NPS PharmaceuticalsAlternative Names: diabetes therapy research programme - NPS Pharmaceuticals; R 467
Latest Information Update: 14 May 2007
At a glance
- Originator NPS Pharmaceuticals
- Mechanism of Action Calcium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 29 Jul 2003 Preclinical trials in Diabetes mellitus in USA (unspecified route)